Also Known As
NN703 · NN-703
Overview
Tabimorelin is an orally active ghrelin receptor agonist that stimulates growth hormone release. Developed by Novo Nordisk but discontinued after Phase II trials due to CYP3A4 inhibition concerns.
Mechanism of Action
Potent agonist of the ghrelin/growth hormone secretagogue receptor (GHSR). Oral bioavailability ~30%. Mechanism-based inhibitor of CYP3A4.
Quick Reference
Notes
Development discontinued due to CYP3A4 inhibition. May cause drug interactions. Research compound only.
Dosing Protocol
Pharmacokinetics
Administration
Special Instructions
Development discontinued by Novo Nordisk due to CYP3A4 inhibition. Research compound only. Significant drug interaction potential.
Warnings
Contraindications
Drug Interactions
Possible Side Effects
Legal & Regulatory
Pregnancy
Molecular Data
No sources available yet.
Related Peptides
No community data available yet. Be the first to add this peptide to your inventory!